Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 13/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25614895 | 1.00 | CHRNA3 (0.50) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL25614278 | 0.83 | CHRNB4 (0.54) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL30811741 | 0.83 | CHRNA3 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL6190438 | 0.80 | CHRNB2 (0.68) | CHRNA3CHRNB4CHRNB2CHRNA4 | |
| SCHEMBL30811670 | 0.78 | CHRNB4 (0.40) | CHRNA3CHRNB4CHRNB2CHRNA4CCR6 | |
| SCHEMBL30665748 | 0.77 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL30811721 | 0.77 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL29108020 | 0.77 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL30665749 | 0.77 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL29108032 | 0.77 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | CHRNA3 3573/4885CHRNB4 4350/4885CHRNB2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.